Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
A U.S. Senate Committee on Foreign Releations hearing on the nomination of Dr. Deborah Birx to be the next Ambassador at Large and U.S. Global AIDS […]
Integrated TB and HIV treatment adds up to increased survival, improved efficiencies, and new funding focus
Around much of the world where rates of HIV-tuberculosis co-infection are highest, one of the challenges killing patients has been the wait to discover if their […]
WHO’s PQP: How affordable antiretroviral and other treatments owe much to “little known part of WHO” reliant on two funders
In 1999, a small South Africa study revealed disturbing news about a medicine used in first line directly observed therapy for tuberculosis: it contained the right […]
“Before there was PEPFAR or the Global Fund, Dr. Birx was leading the charge in changing this disease,” Sen. Ben Cardin (D-MD) said Thursday, as he […]